PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and non-selective melanocortin receptor agonist (MC3R/MC4R) derived as an active metabolite of Melanotan II. FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, bremelanotide enhances sexual desire by activating MC4R in brain reward and arousal pathways, increasing dopamine release in the nucleus accumbens and medial preoptic area. This educational protocol presents a once-daily subcutaneous approach with gradual titration using a practical dilution for clear insulin-syringe measurements.
